Literature DB >> 17068065

Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope.

Leyla Kazkaz1, Hubert Marotte, Mayassa Hamwi, Marie Angélique Cazalis, Pascal Roy, Bruno Mougin, Pierre Miossec.   

Abstract

OBJECTIVE: To investigate whether ethnic differences exist in the effect of the shared epitope and selected cytokine gene polymorphisms on the susceptibility and severity of rheumatoid arthritis in Syria (Damascus) and France (Rhône-Alpes area).
METHODS: 156 patients with rheumatoid arthritis and 120 healthy controls from Syria were compared with 512 patients with rheumatoid arthritis and 471 healthy controls from France. Shared epitope status, cytokine gene polymorphisms interleukin (IL)-1B +3954, IL-1RN +2018 and tumour necrosis factor alpha promoter (-238 and -308) were analysed by enzyme-linked oligosorbent assay. Joint destruction was defined by a right wrist Larsen score > or =2. Odds ratios (ORs) were calculated.
RESULTS: In both countries, a dose effect was observed between the shared epitope copy number and rheumatoid arthritis (Syria: OR 1 v 0 copies = 1.6, p = NS; OR 2 v 0 = 15.3, p<0.01; and France: OR 1 v 0 = 2.3, p<0.001; OR 2 v 0 = 7.2, p<0.001). A dose effect was also observed between the shared epitope copy number and joint destruction in Syria (OR 1 v 0 = 2.2, p = NS; OR 2 v 0 = 9.9, p<0.01) and France (OR 1 v 0 = 1.8, p<0.01; OR 2 v 0 = 4.8, p = 0.001). The dose effect of the shared epitope was greater in Syria than in France. Only the -238 tumour necrosis factor alpha polymorphism was associated with joint destruction in the Syrian population (p<0.05). However, after adjustment for age, sex, disease duration and rheumatoid factor for severity, this association disappeared.
CONCLUSION: The frequency of the shared epitope was increased in the French population with rheumatoid arthritis and in controls, but the association between the shared epitope and joint destruction was more pronounced in the Syrian population, with an OR of almost 10 for the homozygotes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068065      PMCID: PMC1798494          DOI: 10.1136/ard.2004.033829

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  39 in total

1.  Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins.

Authors:  A J MacGregor; H Snieder; A S Rigby; M Koskenvuo; J Kaprio; K Aho; A J Silman
Journal:  Arthritis Rheum       Date:  2000-01

2.  Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis.

Authors:  Martina Fabris; Emma Di Poi; Angela D'Elia; Giuseppe Damante; Luigi Sinigaglia; Gianfranco Ferraccioli
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

3.  IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels.

Authors:  N Buchs; F S di Giovine; T Silvestri; E Vannier; G W Duff; P Miossec
Journal:  Genes Immun       Date:  2001-06       Impact factor: 2.676

4.  Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis.

Authors:  D L Mattey; A B Hassell; P T Dawes; N T Cheung; K V Poulton; W Thomson; A H Hajeer; W E Ollier
Journal:  Arthritis Rheum       Date:  2001-07

5.  A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases.

Authors:  D Jawaheer; M F Seldin; C I Amos; W V Chen; R Shigeta; J Monteiro; M Kern; L A Criswell; S Albani; J L Nelson; D O Clegg; R Pope; H W Schroeder ; S L Bridges ; D S Pisetsky; R Ward; D L Kastner; R L Wilder; T Pincus; L F Callahan; D Flemming; M H Wener; P K Gregersen
Journal:  Am J Hum Genet       Date:  2001-03-09       Impact factor: 11.025

6.  Class II MHC antigens in early rheumatoid arthritis in Bath (UK) and Madrid (Spain).

Authors:  A Balsa; N J Minaur; D Pascual-Salcedo; C McCabe; A Balas; B Fiddament; J L Vicario; N L Cox; E Martín-Mola; N D Hall
Journal:  Rheumatology (Oxford)       Date:  2000-08       Impact factor: 7.580

7.  The association of HLA-DRB genes and the shared epitope with rheumatoid arthritis in Pakistan.

Authors:  K Hameed; S Bowman; E Kondeatis; R Vaughan; T Gibson
Journal:  Br J Rheumatol       Date:  1997-11

8.  A routine assay for the direct analysis of HLA-DR-related shared epitope and B27 alleles in chronic inflammatory arthritis.

Authors:  B Mougin; P Garnero; O Borel; C Compagnon; V Barbalat; H Marotte; P Miossec
Journal:  J Immunol Methods       Date:  2001-10-01       Impact factor: 2.303

9.  IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction.

Authors:  N Buchs; T Silvestri; F S di Giovine; M Chabaud; E Vannier; G W Duff; P Miossec
Journal:  Rheumatology (Oxford)       Date:  2000-10       Impact factor: 7.580

10.  New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study.

Authors:  F Cornélis; S Fauré; M Martinez; J F Prud'homme; P Fritz; C Dib; H Alves; P Barrera; N de Vries; A Balsa; D Pascual-Salcedo; K Maenaut; R Westhovens; P Migliorini; T H Tran; A Delaye; N Prince; C Lefevre; G Thomas; M Poirier; S Soubigou; O Alibert; S Lasbleiz; S Fouix; C Bouchier; F Lioté; M N Loste; V Lepage; D Charron; G Gyapay; A Lopes-Vaz; D Kuntz; T Bardin; J Weissenbach
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

View more
  7 in total

Review 1.  Indigenous Nigeria medicinal herbal remedies: A potential source for therapeutic against rheumatoid arthritis.

Authors:  Uche O Arunsi; Ogbuka E Chioma; Paschal E Etusim; Solomon E Owumi
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-16

Review 2.  Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis.

Authors:  Mohammed Hammoudeh; Abdurhman Alarfaj; Der-Yuan Chen; Hachemi Djoudi; Ehab Youseif; Jian Zhu
Journal:  Clin Rheumatol       Date:  2012-12-15       Impact factor: 2.980

3.  The Clinical Significance of Interleukin-1 Receptor Antagonist +2018 Polymorphism in Rheumatoid Arthritis.

Authors:  Endom Ismail; Omimah Khaled Jaber Nofal; Rajalingham Sakthiswary; Syahrul Sazliyana Shaharir; Radhika Sridharan
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

Review 4.  Circulating interleukin-6 and rheumatoid arthritis: A Mendelian randomization meta-analysis.

Authors:  Bing Li; Yu Xiao; Dan Xing; Xin-Long Ma; Jun Liu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

5.  Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations.

Authors:  Yukinori Okada; Kwangwoo Kim; Buhm Han; Nisha E Pillai; Rick T-H Ong; Woei-Yuh Saw; Ma Luo; Lei Jiang; Jian Yin; So-Young Bang; Hye-Soon Lee; Matthew A Brown; Sang-Cheol Bae; Huji Xu; Yik-Ying Teo; Paul I W de Bakker; Soumya Raychaudhuri
Journal:  Hum Mol Genet       Date:  2014-07-28       Impact factor: 6.150

6.  Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis.

Authors:  Erik J M Toonen; Pilar Barrera; Jaap Fransen; Arjan P M de Brouwer; Agnes M Eijsbouts; Pierre Miossec; Hubert Marotte; Hans Scheffer; Piet L C M van Riel; Barbara Franke; Marieke J H Coenen
Journal:  Arthritis Res Ther       Date:  2012-12-07       Impact factor: 5.156

7.  Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene.

Authors:  Yukinori Okada; Dorothee Diogo; Jeffrey D Greenberg; Faten Mouassess; Walid A L Achkar; Robert S Fulton; Joshua C Denny; Namrata Gupta; Daniel Mirel; Stacy Gabriel; Gang Li; Joel M Kremer; Dimitrios A Pappas; Robert J Carroll; Anne E Eyler; Gosia Trynka; Eli A Stahl; Jing Cui; Richa Saxena; Marieke J H Coenen; Henk-Jan Guchelaar; Tom W J Huizinga; Philippe Dieudé; Xavier Mariette; Anne Barton; Helena Canhão; João E Fonseca; Niek de Vries; Paul P Tak; Larry W Moreland; S Louis Bridges; Corinne Miceli-Richard; Hyon K Choi; Yoichiro Kamatani; Pilar Galan; Mark Lathrop; Towfique Raj; Philip L De Jager; Soumya Raychaudhuri; Jane Worthington; Leonid Padyukov; Lars Klareskog; Katherine A Siminovitch; Peter K Gregersen; Elaine R Mardis; Thurayya Arayssi; Layla A Kazkaz; Robert M Plenge
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.